| INTRODUCTION
As there are multiple options for the pharmacologic treatment during percutaneous coronary interventions (PCI), the decision on which to use can be controversial. While aspirin remains a mainstay for patients with coronary artery disease (CAD), pharmacotherapies with different mechanisms on the platelet and coagulation cascade have progressed.
Newer generation thienopyridines, glycoprotein IIb/IIIa inhibitors, vorapaxar, heparin, direct thrombin inhibitors, and factor Xa inhibitors offer a dizzying array of options and combinations for adjunctive medical therapy during and after PCI. This article aims to summarize the various antiplatelet and anticoagulation therapies available, their mechanisms of action, and the evidence surrounding their use.
| The coagulation and platelet cascade
Before delving into the various pharmacologics used in the cardiac catheterization laboratory, it is important to review the physiology of the coagulation and platelet cascade to help understand the mechanism of each drug.
After endothelial disruption, thrombogenic connective tissue is exposed. The first line of defense, primary hemostasis, is mediated by circulating platelets, which form a "platelet plug." The platelets adhere to glycoprotein receptors on exposed endothelial connective tissue.
After adhesion to the glycoprotein receptors, platelets release substrates such as adenosine diphosphate (ADP) and thromboxane A2 (TxA2) that stimulate platelet aggregation. Secondary hemostasis occurs by triggering of the plasma coagulation proteins. The coagulation cascade consists of intrinsic and extrinisic pathways, with both pathways resulting in factor Xa activation. The intrinsic pathway begins with activation of factor XII, which activates factor XI, which in turn activates factor IX, which then acts with its cofactor, factor VIII, to activate factor X. Activated factor Xa is responsible for the conversion of prothrombin into thrombin, which leads to fibrinogen cross-linking and fibrin mesh.
1 Figure 1 displays the platelet and coagulation cascade, and the site of each pharmacologic interaction. Hemostasis by platelets and the coagulation cascade are closely linked; while activated platelets stimulate the coagulation pathway, certain coagulation proteins involved in the coagulation pathway also stimulate further platelet aggregation.
2 | ANTIPLATELET OVERVIEW
| Aspirin
Aspirin is a cornerstone in the treatment of patients with coronary artery disease (CAD). Aspirin inhibits platelet cyclooxygenase, which is a key enzyme in thromboxane A2 (TXA2) generation. TXA2 triggers a downstream cascade that leads to platelet activation and aggregation.
Aspirin, an irreversible inhibitor, lasts for 7-10 days as an antiplatelet agent.
Large randomized clinical trials demonstrated an approximate 50% reduction in the risk of death or myocardial infarction (MI) in patients with unstable angina (UA) and non-ST elevation MI (NSTEMI) in patients treated with aspirin. 2, 3 However, it is interesting to note that aspirin did not gain FDA approval for treatment of CAD until the late 1980's. 4 The Swedish angina pectoris aspirin trial showed that aspirin therapy led to significant reductions in death and MI in patients with stable angina as well. 5 Due to its demonstrated benefits, aspirin has become routine in all patients with known or suspected CAD. 6 Aspirin in combination with dipyridamole or ticlodipine in comparison to placebo have been noted to reduce the incidence of periprocedural MI after balloon angioplasty (Table 1) . [7] [8] [9] [10] However, studies have failed to show benefit from a combination of aspirin and dipyridamole over aspirin alone in PCI.
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Currently the guidelines for PCI recommend 81-325 mg of aspirin before PCI (325 mg if not on aspirin prior to PCI) and that aspirin should be continued indefinitely after PCI. 12 Because enteric coated aspirin can take 24 h to have full effect, the loading dose can be chewed for a more rapid antiplatelet effect. For maintenance post-PCI, there are data to suggest that 81 mg is as effective as 325 mg in preventing ischemic complications, and associated with a lower rate of major bleeding. 13 The guidelines also recommend using a dose of 81-100 mg in patients taking concomitant thienopyridines. 12 However, aspirin is not benign. Aspirin use places patients at elevated bleeding risk. For patients on dual antiplatelet therapy, guidelines recommend a proton pump inhibitor for all patients with a history of gastrointestinal bleeding (Class 1). 14 In patients at elevated risk for gastrointestinal bleeding (ie, advanced age, concomitant use of steroids, anticoagulants, or nonsteroidal anti-inflammatory drugs), the FIGURE 1 Displays the coagulation cascade and platelet activation. The mechanism of drug interactions 
| Clopidogrel
Clopidogrel, a second generation thienopyridine, binds irreversibly to the P2Y12 receptor preventing adenosine diphosphate (ADP) dependent activation of platelet aggregation. 16 Hepatic CYP450
enzymes are heavily involved in the bioactivation process of clopidogrel, including the CYP2C19 enzyme, which plays a vital role.
Genetic variations may interfere with the efficacy of clopidogrel, including CYP2CI19 polymorphisms which may be present in up to 15-40% of the population. 17 Many observational studies have found an association with clopidogrel resistance and subsequent cardiovascular events after PCI. 18 In one prospective registry, ADAPT-DES, platelet reactivity was assessed using VerifyNow point-of-care assays in patients after PCI with DES. High P2Y12 reaction units (defined as >208) was independently associated with 30-day definite/probable IST (HR = 3.0; P = 0.005), 1 year IST (HR = 2.49; P = 0.001), and myocardial infarction at 2 years (HR =1.33; P = 0.01) (Stone et al, ADAPT DES). It is important to note that clopidogrel resistance is common in diabetics and obese patient. 19 The CAPRIE trial randomized patients (n = 19 185) with atherosclerotic vascular disease to aspirin or clopidogrel for secondary prevention. The primary composite end-point of ischemic stroke, MI or cardiovascular death was statistically lower in the clopidogrel arm (5.32% vs 5.83%, P = 0.043). Clopidogrel reduced the risk of CV events by 9% compared to aspirin with a statistically significant reduction in gastrointestinal bleeding (P = 0.05). 20 However, this trial did not address the combination of clopidogrel and aspirin. The benefit of clopidogrel in addition to aspirin was established in the CURE trial, which randomly assigned patients (n = 12 562) presenting with NSTEMI to aspirin or aspirin/clopidogrel (300 mg loading dose followed by 75 mg/day) immediately after presentation. At an average follow up of 9 months, combination therapy led to a significant reduction in the combined primary endpoint of cardiovascular death, nonfatal MI, or stroke (9.3% vs 11.4%). 21 Of note, approximately 60% of these patients did not undergo revascularization. However, the subgroup analysis of patients that had PCI confirmed benefit with dual antiplatelet therapy (DAPT) of clopidogrel and aspirin over aspirin alone. 22 Table 3 displays the trials showing benefit of DAPT over ASA alone for stable ischemic heart disease undergoing PCI and ACS.
The optimal loading dose of clopidogrel has been thoroughly debated. In the CURRENT/OASIS trial, there was no difference in the primary endpoint of cardiac death, stroke or MI at 30 days in patients presenting with acute coronary syndrome (ACS) who received 300 mg versus 600 mg of a clopidogrel load (4.4% vs 4.2%, P = 0.3). 23 However, among those patients who underwent PCI, the incidence of the primary endpoint was reduced (3.9% vs 4.5% HR = 0.85; 95%CI: 0.74-0.99; P = 0.04) in patients receiving the 600 mg dose. The incidence of definite in-stent thrombosis was reduced in the 600 mg arm (1.6% vs 2.3%; HR = 0.68; 95%CI: 0.55-0.85; P < 0.001), at the cost of an increased risk of major bleeding (2.5% vs 2.0%; HR = 1.24; 95%CI:
1.05-1.46; P = 0.01). 23 A subsequent meta-analysis (n = 25 383)
showed that a 600 mg dose reduced the relative risk of major adverse cardiovascular events (MACE) by 34% in comparison to 300 mg, with no statistical increase in major bleeding. 24 Recent trials have shown that newer P2Y12 inhibition are more effective in the ACS patient population. This prompted the 2015 FDA 
| Prasugrel
Prasugrel, an irreversible thienopyridine ADP receptor antagonist, has a more rapid onset of action and greater platelet inhibition than clopidogrel. 25, 26 While prasugrel is a prodrug (similar to clopidogrel), its conversion occurs more rapidly and is not affected by genetic polymorphisms in CYP2C19 enzymes. 27 Prasugrel (60 mg load followed by 10 mg daily) was compared to clopidogrel in patients with ACS in the TRITON-TIMI 38 trial. 28 Of the 13 000 plus patients randomized to either clopidogrel or prasugrel, the primary endpoint (death from cardiovascular causes, nonfatal MI, or nonfatal stroke) occurred in 9.9% of patients receiving prasugrel, and 12.1% of patients receiving clopidogrel (P < 0.001). Stent thrombosis was 1.1% in the prasugrel arm versus 2.4% in the clopidogrel arm (P < 0.001), and the improvement in stent thrombosis and clinical outcomes occurred very early. However, non-CABG related major bleeding was greater in the prasugrel arm (2.4% vs 1.8% P = 0.03).
The authors conducted a post-hoc subgroup analysis to identify patients who may not have benefited from prasugrel administration. In patients with previous stroke or transient ischemic attack (TIA), there was net harm from prasugrel (hazard ratio, 1.54; 95%CI, 1.02 to 2.32; P = 0.04). In patients that were 75 years of age or older and/or in patients weighing less than 60 kg, there was no net benefit from prasugrel. 28 Therefore, a prior history of stroke/TIA is an absolute contraindication to Prasugrel usage, and age 75 or older and/or weight less than 60 kg are relative contraindications for Prasugrel usage. 15 In the TRITON TIMI 38 trial, prasugrel was given after coronary angiography. Results from the ACCOAST trial suggest that pretreatment of ACS patients with prasugrel did not reduce MACE, and resulted in more bleeding than when prasugrel was given at the time of PCI. 29 Guidelines therefore discourage pretreatment with prasugrel in ACS patients.
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Both ticagrelor and prasugrel have a faster onset than clopidogrel, however, prasugrel has a slower offset than ticagrelor (by 1-2 days). In vivo comparison of ticagrelor and prasugrel has shown that platelet inhibition is more potent for ticagrelor. 31 At present, there are no direct randomized comparisons of ticagrelor versus prasugrel with respect to clinical outcomes.
| Ticagrelor
In contrast to thienopydridines, ticagrelor is an allosteric antagonist of the ADP receptor which binds reversibly to the P2Y12 receptor, preventing ADP-mediated activation and thereby reducing platelet aggregation. Ticagrelor is not a prodrug, so hepatic conversion to an active metabolite like clopidogrel and prasugrel is not required. In patients with stable CAD, the onset of inhibition is more rapid than clopidogrel: 41% within 30 min, with a peak effect 2 h post administration. 32 The ONSET/OFFSET study was a double-blind randomized study of patients with stable CAD on aspirin. Two hours after loading, 90% of patients in the ticagrelor arm achieved inhibition of platelet aggregation >70% versus 16% in the clopidogrel-treated arm. Ticagrelor achieved higher platelet inhibition throughout the study. 32 Ticagrelor was compared to clopidogrel in 18 624 ACS patients in the PLATO trial. At 12 months, the composite primary end point (death from vascular causes, MI, or stroke) occurred in 9.8% of patients receiving ticagrelor versus 11.7% of patients receiving clopidogrel (HR 0.84, 95%CI 0.77-0.92, P < 0.001), however, there was no early benefit in the first 30 days. There was no significant difference in the rates of CABG related bleeding, intracranial hemorrhage, or transfusion rates despite the increased potency of ticagrelor. 33 However, non-CABG related major bleeding was increased with ticagrelor (4.5% vs 3.8%, P = 0.03) It is important to note that the majority of patients received ticagrelor pre-coronary angiography, which is unlike the TRITON TIMI 38 trial for prasugrel. 28 The benefit of ticagrelor beyond 12 months was explored in the PEGASUS TIMI-54 trial. In the 21 162 patients randomized to ticagrelor or placebo 1 year after an MI, ticagrelor reduced the risk This reduction in MACCE was driven primarily by a reduction in MI.
Compared to placebo, rates of TIMI major bleeding were higher with ticagrelor; 2.6% with 90 mg, 2.3% with 60 mg, and 1.06% with placebo (P < 0.001 for each dose of ticagrelor vs placebo). Since the two ticagrelor doses were associated with similar efficacy while rates of TIMI major bleeding were numerically lower with the 60 mg dose of ticagrelor than with the 90 mg dose, the 60 mg dose is preferred after 1 year. 34 Ticagrelor has recognized adverse effects. In the PLATO trial, during the first week, there was an increase in asymptomatic ventricular pauses greater than 3 s in the ticagrelor arm (5.8 vs 3.6%, P = 0.01). However, there were no differences in syncope, heart block, or pacemaker insertion. Dyspnea was another side effect reported in up to 14% of patients in the ticagrelor arm. As a result, almost 1% of patients discontinued the drug, Cannon et al. 33 In the PEGASUS-TIMI 54 trial, dyspnea occurred in 19% of patients dosed at 90 mg of ticagrelor, and 16% in patients on 60 mg of ticagrelor.
Interestingly, the rates of drug discontinuation because of dyspnea observered with ticargelor in this trial were higher than in PLATO (6.5% at 90 mg dosing, and 4.55% at 60 mg). 34 The authors hypothesized that this increased discontinuation was because the patients in PLATO frequently associated their transient dyspnea with their acute illness. One other concern with ticagrelor is its twice-daily dosing, which may affect patient compliance.
| Cangrelor
Cangrelor is a direct acting intravenous P2Y12 receptor inhibitor.
Unlike clopidogrel and prasugrel, (with 7-10 days of antiplatelet effect) cangrelor is a reversible inhibitor which reaches steady-state concentrations within minutes, and recovery of platelet function is rapid (within 1 h) after discontinuation. 35 Based on the results of the CHAMPION trials, cangrelor was FDA approved as an adjunctive medicine in PCI. 36 CHAMPION PCI compared the infusion of cangrelor with clopidogrel load upon discontinuation of the infusion with a 600 mg load of oral clopidogrel prior to PCI in patients with ACS (1:1 randomization of 8877 subjects). Cangrelor usage was not superior to an oral loading dose of clopidogrel in reducing the composite end point of death from any cause, myocardial infarction, or ischemia-driven revascularization at 48 h (7.5% vs 7.1%). 37 In another RCT, 5632
patients were randomized to receive clopidogrel 600 mg versus cangrelor pre-catheterization. Enrollment was stopped when an interim analysis concluded the trial would be unlikely to show superiority for the primary end point. There was no significant difference in the rate of blood transfusion (1% in cangrelor group vs 0.6%, P = 0.13), but there was an increase in major bleeding in the cangrelor group (5.5% to 3.5%, P < 0.001). 38 While neither of the initial CHAMPION studies showed a benefit for cangrelor, a prespecified pooled analysis of the data from both CHAMPION trials showed that when the universal definition of MI was applied, cangrelor significantly reduced the primary end point. 39 This led to the CHAMPION PHOENIX trial, which looked at the addition of cangrelor to clopidogrel plus aspirin in patients who were P2Y12 receptor inhibitor naïve (n = 11 145) undergoing PCI (stable angina and ACS) to reduce the incidence of death, myocardial infarction, ischemiadriven revascularization, or stent thrombosis at 48 h after randomization. The rate of events was 4.7% in the cangrelor group and 5.9% in the clopidogrel group (P = 0.005), primarily driven by a 20% relative reduction in the rate of MI. Stent thrombosis at 48 h was also significantly reduced in the cangrelor arm. 40 These results were maintained at 30 days across all prespecified subgroups. 41 It is important to note that cangrelor may block P2Y12 receptor binding of other true thienopyridines (but not ticagrelor). When clopidogrel is given during a cangrelor infusion, clopidogrel is unable to bind to the P2Y12 receptor and exhibit its antiplatelet effect since the receptor is already occupied by cangrelor. However, when clopidogrel is administered after cangrelor infusion, its antiplatelet effects are not decreased since cangrelor has such a rapid offset of action. 33 Given these unique characteristics, some physician recommend concomitant ticagrelor to avoid concerns about timing of later administration of clopidogrel.
In all of the CHAMPION trials, cangrelor led to an increased bleeding rate, however, major and life-threatening bleeds were not statistically different. 42 In the CHAMPION trials, patients treated with cangrelor experienced a higher incidence of transient dyspnea (1.1% vs 0.4%; P < 0.001). 35 However, drug discontinuation because of the dyspnea was negligible.
In summary, cangrelor is a unique PDY12 inhibitor with its rapid onset and offset. Based on the results and post-hoc analysis of the CHAMPION trials the ESC guidelines endorse the use of cangrelor as a Class IIb (LOE A) for NSTEMI patients. eptifibitide, tirofiban, and abciximab. Tirofiban and eptifibatide bind reversibly to the GP IIb/IIIa receptor. Since the drug-to-receptor ratio is high, platelet infusion is not effective in cases of severe bleeding. In contrast, the drug-to-receptor ratio is low with abciximab and the circulating pool of abciximab is bound to platelets, therefore platelet transfusion can be effective in its reversal in instances of severe bleeding. Table 4 displays the differences in pharmacokinetics/ dynamics between the three GPI ( Because of the increased bleeding risk and concerns about acute and delayed thrombocytopenia with intravenous abciximab, alternative routes for GPI was studied. Oral loading proved inefficient, but several small studies suggested that intracoronary GPI may have good outcomes. 46 In the largest randomized trial comparing intravenous to intracoronary administration in ACS patients (n = 105), intracoronary delivery of abciximab bolus was not associated with improved angiographic results, infarct size, and/or clinical outcomes. 47 However, a meta-analysis of 3916 patients from various trials showed that intracoronary use resulted in 45% reduction in relative risk for major cardiovascular events (RR; 95% confidence interval [CI], 24-60%), with no effect on overall mortality. 48 Because there are no definitive results, the guidelines currently advise the route of administration be at the operator's discretion (class IIb). 30 The timing of GPI administration was investigated in several trials.
The ACUITY Timing trial was conducted to determine the benefit of upstream use of GP IIb/IIIa inhibitors in patients with moderate and high risk ACS undergoing an early, invasive treatment strategy compared to deferred use. 49 At 30 days, composite ischemia was significantly reduced in the deferred strategy compared to upstream administration, 7.1% versus 7.9%, respectively. 49 In addition, deferred used of GPI had significantly lower rates of major bleeding at 30 days compared to upstream use (4.9% vs 6.1%; P < 0.001 The ubiquitous use of DAPT in the treatment of ACS has dampened the benefit of GPI seen in earlier trials. Under current guidelines, the routine use of GPI is not recommended. GPI have recently been reduced from a class I to a class IIa recommendation in selected patients with the use of UFH, including individuals with "high thrombus burden or inadequate P2Y12 receptor antagonist loading." 30 The upstream use of GPI has been shown to be neither beneficial nor harmful, and current guidelines give it a class IIb recommendation.
Additionally, the route of administration remains controversial, and the option of intracoronary versus intravenous administration is at the operator's discretion (Class IIB, LOE B). 30 
| Vorapaxar
Vorapaxar, an antagonist of the protease-activated receptor-1 (PAR- Platelet recovery ∼4-8 h after discontinuation. Platelet transfusion not effective for reversal.
Platelet recovery ∼4-8 h after discontinuation. Platelet transfusion not effective for reversal.
3 years, although it increased the risk of moderate to severe bleeding and intracranial hemorrhage (particularly in patients with a prior history of cerebrovascular event [CVA] ). The subgroups that fared best with vorapaxar were patients with a history of MI and/or peripheral artery disease (PAD). 54 Another study in patients presenting with NSTE-ACS (n = 12 944) randomized to DAPT or DAPT with vorapaxar found that the addition of vorapaxar added no benefit and was associated with an increase in intracranial hemorrhage. 55 However, this study was dedicated to patients with ACS, who were on antithrombotic therapy as well. Therefore, it cannot be concluded that the rate of intracranial hemorrhage was related to intensive antithrombotic therapy or there is a link between vorapaxar and intracranial bleeding. 55 According to the ACC/AHA 2016 PAD guidelines, the addition of vorapaxar to aspirin and clopidogrel is a class IIb (uncertain) indication in patients with symptomatic PAD. 56 However, a RCT in stable patients with prior MI, PAD, or CVA found that the addition of vorapaxar to standard background antiplatelet therapy reduced the incidence of very late stent thrombosis (HR = 0.65; P = 0.037) compared to placebo. 57 Additionally, in patients with symptomatic PAD, vorapaxar lead to a reduction in acute limb ischemia. 58 Currently, there does not appear to be a role of vorapaxar use in the cardiac catheterization laboratory, though certain patients may benefit from it down the road.
| Anticoagulation overview
There are currently multiple anticoagulants that can be used for PCI.
The most commonly used are unfractionated heparin (UFH) and direct thrombin inhibitors (DTI). This section will discuss UFH, low molecular weight heparin (ie, enoxaparin), and direct thrombin inhibitors (ie, bivalirudin) and their use during PCI. | 699 thrombocytopenia (HIT), the potential to be inhibited by platelet factor 4, and its inability to inhibit fibrin-bound thrombin.
| Direct thrombin inhibitors
The direct thrombin inhibitors (DTI) include bivalirudin, lepiruban, and argatroban, with the most commonly being bivalirudin. DTIs inactivate circulating thrombin at the active binding site, and can also inactivate clot-bound thrombin (unlike heparin products). Bivalirudin is excreted through the kidneys, and has a half-life of approximately 25 min. The recommended starting dose is a bolus of 0.75 mg/kg, followed by an infusion of 1.75 mg/kg/h (which can be discontinued after PCI is completed, although a 4 h infusion in STEMI pts is recommended by some). Bivalrudin can be used in renally impaired patients with dose modification. 64 The BRIGHT trial was conducted to compare the use of bivalirudin and heparin with or without tirofiban in 2194 patients with acute MI undergoing primary percutaneous coronary intervention (PCI). Among patients with acute MI undergoing primary PCI, the use of bivalirudin with a 3-h post procedure PCI infusion resulted in a decrease in adverse events, driven mainly by a significant reduction in bleeding events. Net clinical adverse events (ischemic and bleeding events) at 30 days were 8.8% in the bivalirudin only group, 13.2% in the heparin only group, and 17% in the heparin plus tirofiban group (P < 0.001). 51 The ACUITY trial, which evaluated the use of bivaliriduin alone, bivalirudin plus a GPI, or unfractionated heparin plus a GPI, in 13 819 patients with ACS, had similar results to the BRIGHT trial. Bivalirudin alone, bivalirudin plus GPI, and heparin plus GPI met the 30 day noninferiority endpoint of the composite ischemia end point (7.8%, 7.7%, and 7.3%, respectively, P < 0.001). In regards to major bleeding, bivalirudin alone was superior to either bivalirudin plus GPI or heparin plux GPI (3.0%, 5.3%, and 5.7%, P < 0.001). 49 The EUROMAX trial, which randomized 2218 patients to bivalirudin versus UFH (with provisional use of GPI, which occurred in almost 70% of patients), the primary composite of death and/or major bleeding was reduced in the bivalirudin arm (5.1% vs 8.5%, P > 0.005), mostly driven by reduced bleeding risk. 65 This was similar to the results in the ACUITY trial.
However, acute stent thrombosis within 24 h was worse in the bivalirudin arm (1.1% vs 0.2%, P < 0.01). 66 Similar results were discovered in the HORIZONS-AMI, which randomized 3602 patients with STEMI to bivalirudin monotherapy versus UFH + GPI. At 30 days, the composite endpoint (death, stroke, MI, unplanned revascularization, and major bleeding) favored bivalirudin (9.2 vs 12.1%, P = 0.005). 67 This outcome was driven by a reduction in major bleeding (4.9% vs 8.3%, P < 0.001). However, instent thrombosis within 24 h was also increased in the bivalirudin Bivalirudin versus heparin (with or without tirofiban) N = 2194 Net clinical adverse events (ischemic and bleeding events) at 30 days were 8.8% in the bivalirudin only group, 13.2% in the heparin only group, and 17% in the heparin plus tirofiban group (P < 0.001).
EUROMAX trial 65 Bivalirudin versus UFH (provisional use of GPI occurred in almost 70% of patients)
The primary composite of death and/or major bleeding was reduced in the bivalirudin arm (5.1% vs 8.5%, P > 0.005), mostly driven by reduced bleeding risk. However, acute stent thrombosis within 24 h was worse in the bivalirudin arm (1.1% vs 0.2%, P < 0.01).
ACUITY trial 49 Bivaliriduin alone versus bivalirudin plus a GPI versus unfractionated heparin plus a GPI N = 13 819 Bivalirudin alone, bivalirudin plus GPI, and heparin plus GPI met the 30 day noninferiority endpoint of the composite ischemia end point (7.8%, 7.7% and 7.3%, respectively, P < 0.001). Bivalirudin alone was superior to either group in regards to major bleeding (3.0%, 5.3%, and 5.7%, P < 0.001).
HEAT-PPCI trial 69 Bivalirudin versus heparin monotherapy N = 1829 MACE (cardiac death, re-infarction, target lesion revascularization and stroke) at 30 days was more common in the bivalirudin arm (8.7% vs 5.7%, P = 0.01) MATRIX trial 70 Bivalirudinversus heparin (then further randomized those patients in the bivalirudin arm to post-PCI bivalirudin infusion versus none)
The rate of net adverse clinical events at 30 days was not significantly lower with bivalirudin than with heparin (11.2% vs. 12.4%, P = 0.12). Post-PCI bivalirudin infusion did not significantly decrease the rate of adverse events (and stent thrombosis) in comparison to no post-PCI infusion (11% vs 11.9%, P = 0.34).
VALIDATE-
SWEDEHEART trial 71 Bivalirudin versus heparin monotherapy N = 6006 Composite of death from any cause, myocardial infarction, or major bleeding during 180 days of follow-upoccurred occurredin 12.3% in the bivalirudin arm versus 12.8% in the heparin arm (P = 0.54).
group (1.3% vs 0.3%, P < 0.001). These findings warranted further investigation on the questions of how to reduce in-stent thrombosis with the use of bivalirudin. In a subgroup analysis of the HORIZONS-AMI, Dangas et al found that in-stent thrombosis rates were significantly reduced in patients from the bivalirudin arm who received 600 mg of clopidogrel versus 300 mg. 68 The prevalence of GPI usage in previous trials may have confounded the comparison of bivalirudin to heparin. HEAT-PPCI was an open label, single center, randomized trial designed to compare bivalirudin to UFH monotherapy (though GPI was used in 15.5 vs 13.5% of patients in the bivalirudin and heparin arms, respectively).
MACE (cardiac death, re-infarction, target lesion revascularization, and stroke) at 30 days was more common in the bivalirudin arm (8.7% vs 5.7%, P = 0.01). Similar to the previous trials, in-stent thrombosis was significantly increased in the bivalirudin arm (3.4% vs 0.9%, P < 0.005), while major bleeding rates were similar in both arms (3.5% vs 3.1%, P = 0.39). (11% vs 11.9%, P = 0.34). 70 The VALIDATE-SWEDEHEART trial also found similar results in 6006 patients with ACS randomized to bivalirudin or heparin. In this trial, newer P2Y12 inhibition was more prevalent, radial access predominant and GPI use was rare. The primary end point was a composite of death from any cause, myocardial infarction, or major bleeding during 180 days of followup. The primary end point occurred in 12.3% in the bivalirudin arm versus 12.8% in the heparin arm, which was not statistically significant (P = 0.54). 71 Table 6 summarizes the major trials comparing bivalirudin to heparin in ACS.
Despite the multiple trials on bivalirudin, questions remain. The impact of pre-use of UFH, newer P2Y12 inhibition drugs and combination with GPI on the bleeding versus thrombosis risk are all topics that still need to be definitively addressed. Currently, either bivalirudin or UFH for anticoagulation during NSTEMI and STEMI is a Class 1 recommendation in both the AHA and EU guidelines. 15, 30, 43 Additionally, bivalirudin has a Class 1b recommendation per the guidelines for all non-ACS PCI. 12 
| LMWH
Low molecular weight heparins (LMWH) are short polysaccharide chains which act through inhibition of factor Xa. Unlike UFH, they are too small to bind and potentiate ATIII. LMWH are not recommended in patients with impaired renal function, since they are cleared by a kidney-dependent mechanism. 59 Advantages of LMWH include a more predictable effect that does not need to be monitored in patients with normal renal function, lack of inhibition by platelet factor 4, option for subcutaneous dosing, and a lower risk of HIT.
Enoxaparin has been compared to UFH in multiple trials. 72 in the enoxaparin arm (9.1% vs 7.6%; P = 0.008). 72 However, the excess bleeding in the enoxaparin arm might have been explained by the 7.7% crossover from UFH to enoxaparin in the SYNERGY trial.
Patients who crossed over had an increased incidence of bleeding and death/MI at 30 days, which may have influenced the endpoint. 73 The ATOLL trial compared enoxaparin to UFH (n = 910) in patients with STEMI undergoing primary PCI. While there was a trend toward reduction in the primary endpoint (30-day incidence of death, complications of MI, procedure failure, or major bleeding) with Enoxaparin compared to UFH, the results were not statistically significant (28% vs 34%, P = 0.06). There was no difference in major bleeding (5% vs 5%; P = 0.79). 74 Multiple other trials also compared enoxaparin to heparin. A meta-analysis of 23 trials (n = 30 966) found that enoxaparin was associated with significant reductions in the composite of death, with a relative risk reduction of 34% (P < 0.001), complications of MI (relative risk reduction of 32%, P < 0.001), and incidence of major bleeding (20% relative risk reduction, P = 0.009) in patients undergoing PCI (stable and ACS). 75 Though this data appears to favor LMWH, the use of LMWH remains low because of several issues. Its anticoagulation cannot be monitored by ACT. Unlike UFH, protamine only partially reverses LMWH, which is concerning for patients at high bleeding risk.
Clearance of LMWH is decreased in patients with renal impairment.
Dose reduction and adjustment based on anti-factor Xa levels is suggested in patients with renal impairment (creatinine clearance less than 30 mL/min). Additionally, the half-life of LMWH is much longer than intravenous (IV) UFH, so if femoral access is obtained, manual removal must be delayed at least another 4-6 h and failure of a closure device can become complicated. Crossover between UFH and LMWH should be avoided, as these patients have worse outcomes. 73 Therefore, the ACC/AHA guidelines give a IIb recommendation for the use of LMWH during PCI. for cangrelor use will continue to evolve with further investigation.
The modern use of DAPT with aspirin and thienopyridines has decreased the prevalence of GPI. However, it is important to identify patients that may benefit from the addition of a GPI, identified in the guidelines as those with inadequate P2Y12 receptor antagonist loading or patients with high thrombus burden. Vorapaxar, an antagonist of PAR-1, is another pharmacologic that inhibits platelet aggregation. Thus far, there does not appear to be a role for vorapaxar in PCI.
There are currently multiple anticoagulant agents that can be used for PCI. UFH and bivalirudin remain the two most commonly used. It is therefore important to recognize the benefits and limitations of each, including the possible relative increase of in-stent thrombosis for bivalirudin monotherapy versus the increased intraprocedural monitoring requirements and risk of HIT with heparin. Additionally, there is excellent data on the use of LMWH, however its use remains low for practical reasons. Table 7 displays the operator's options along with loading doses of all these drugs for quick reference while in the cardiac catheterization laboratory. With multiple pharmacologic options for PCI, it is essential that interventionists remain up to date and recognize the potential implications of initiating each drug.
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